麻豆传媒

ARISE lays the ground work for registrational trial of Arikayce in earlier treatment setting

AHI dipped by as much as 40% in patients who took sulthiame, but CPAP is still the gold standard

Asthma drug may benefit patients with blood eosinophil counts indicative of type 2 inflammation

NOTUS study confirms fewer exacerbations with biologic for patients on maximum inhaled therapy

Patients benefited from clarithromycin or moxifloxacin plus rifampin/ethambutol

However, treated patients were less likely to develop ARDS, respiratory dysfunction

However, trial results don't affirm safety risks suggested by other studies

Healthcare utilization for respiratory illness halved while quality of life, symptoms improved

An open-label extension trial of pamrevlumab was cancelled due to these results

"These are among the two most exciting sets of results we've seen," researcher says

Millions in the U.S. may be reclassified, changing work eligibility, disability compensation

Roundup of news on pollution exposures also delves into interstitial lung disease, sarcoidosis

Ensifentrine also reduced moderate-to-severe exacerbations

Separate trial analysis of tezepelumab showed no significant differences by sex